Full TitlePhase 1 Study of Precision CRT for Liver-Dominant Metastatic Pancreatic Cancer with Homologous Recombination Deficiency (PreCISeRT)
Researchers are doing this study to assess the combination of conformal radiation therapy (RT) and standard chemotherapy in people with metastatic pancreatic cancer that has spread to the liver. They want to find the highest safe and effective dose of conformal RT that can be given to the liver when combined with chemotherapy. Higher doses of conformal RT will be delivered to the areas of the liver where tumors can be seen, and a lower dose to the entire liver.
All participants in this study will have pancreatic cancer with a homologous recombination deficiency (HRD). When people have cancer with HRD, their cancer cells have a harder time repairing themselves. Cancer that has HRD can be more vulnerable to treatments that damage DNA in cancer cells, such as chemotherapy and RT.
Participants in this study will receive cisplatin and gemcitabine before and after they receive conformal RT and only cisplatin during the two weeks when they receive RT. Cisplatin and gemcitabine together is a standard treatment for metastatic pancreatic cancer. Researchers think that combining cisplatin alone with conformal RT will be more effective than either treatment alone.
To be eligible for this study, patients must meet several requirements, including
- Participants must have pancreatic cancer that has spread to the liver.
- There must be at least one liver tumor that is 7 cm or less in size.
- Patients must be able to walk and do routine activities for more than half of their normal waking hours.
- This study is for people age 18 and older.
For more information about this study and to ask about eligibility, please contact the office of Dr. Marsha Reyngold at 631-623-4267.